Trinity Biotech

Trinity Biotech EBITDA per Employee

The EBITDA per Employee of Trinity Biotech (TRIB) as of Nov 20, 2026 is -19,716.75 USD. In the previous year, EBITDA per Employee was -36,554.40 USD — a change of -46.06% (higher).

EBITDA per Employee

-19,716.75USD

YoY

-46.06%

Last updated:

EBITDA per Employee of Trinity Biotech is 2025 -19,716.75 USD. EBITDA per Employee of Trinity Biotech was 2024 -36,554.40 USD. It decreases by -46.06% higher compared to the previous year.

The Trinity Biotech EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
10,709.84 USD
Jan 1, 2019
5,595.85 USD
Jan 1, 2020
2,564.77 USD
Jan 1, 2021
6,801.38 USD
Jan 1, 2022
-26,371.33 USD
Jan 1, 2023
-46,709.84 USD
Jan 1, 2024
-36,554.40 USD
Jan 1, 2025
-19,716.75 USD
The Trinity Biotech EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-19,716.75USD-46.06%
-36,554.40USD-21.74%
-46,709.84USD+77.12%
-26,371.33USD-487.73%
6,801.38USD+165.19%
2,564.77USD-54.17%
5,595.85USD-47.75%
10,709.84USD+3.25%
10,373.06USD-24.02%
13,652.85USD-41.52%
23,345.42USD-25.32%
31,260.79USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

EBITDA per Employee of Trinity Biotech is -19,716.75 USD in 2025.

EBITDA per Employee of Trinity Biotech changed from -36,554.40 USD to -19,716.75 USD, representing a -46.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Trinity Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Trinity Biotech

All Key Metrics — Trinity Biotech